Digital innovation in clinical trials

Strategic implications for drug and device development

Scott Gottlieb
23rd commissioner of the FDA
Shwen Gwee
VP of Global Digital Strategy
Bristol Myers Squibb
Joel Haspel
SVP Strategy, Science Group

Digital innovation has had a significant impact on the life sciences industry over the past two years. Remote monitoring tools have transformed clinical development with promises of increased trial quality, greater efficiency and stronger patient engagement – all at a lower cost. At the same time, these new tools introduce regulatory and clinical challenges, requiring drug/device developers as well as regulators to adapt and transform to keep pace with the rapidly changing environment.

In an interactive and invitation-only forum, our expert panel tackles pressing questions and debate their implications with attendees.